1,064,000 Shares in HilleVax, Inc. (NASDAQ:HLVX) Bought by Braidwell LP

Braidwell LP acquired a new position in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,064,000 shares of the company's stock, valued at approximately $1,873,000. Braidwell LP owned 2.14% of HilleVax as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Frazier Life Sciences Management L.P. raised its stake in HilleVax by 8.5% during the second quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company's stock worth $153,523,000 after acquiring an additional 835,590 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of HilleVax during the 2nd quarter worth about $6,960,000. Trium Capital LLP bought a new position in HilleVax during the 3rd quarter valued at about $798,000. Ensign Peak Advisors Inc boosted its position in HilleVax by 164.8% in the second quarter. Ensign Peak Advisors Inc now owns 311,784 shares of the company's stock valued at $4,508,000 after buying an additional 194,038 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in HilleVax during the second quarter worth about $3,844,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a report on Monday, August 12th. Six investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.00.

HilleVax Stock Performance

Shares of NASDAQ HLVX traded up $0.01 during trading on Friday, reaching $1.93. The company had a trading volume of 64,286 shares, compared to its average volume of 421,562. The stock has a market cap of $96.13 million, a PE ratio of -0.62 and a beta of 0.78. HilleVax, Inc. has a 52 week low of $1.55 and a 52 week high of $20.22. The business's 50 day moving average price is $1.84 and its 200-day moving average price is $5.13.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.10). Equities analysts anticipate that HilleVax, Inc. will post -2.64 earnings per share for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.